Research Analysts Offer Predictions for ASND FY2024 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Leerink Partnrs lifted their FY2024 earnings estimates for Ascendis Pharma A/S in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will earn ($6.44) per share for the year, up from their previous estimate of ($6.50). The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.27) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($1.90) EPS, Q2 2025 earnings at ($1.81) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($7.12) EPS and FY2026 earnings at ($2.00) EPS.

Several other equities analysts also recently commented on ASND. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Oppenheimer cut their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. JPMorgan Chase & Co. reduced their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price on the stock. Finally, TD Cowen decreased their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Stock Up 2.3 %

Shares of ASND opened at $131.06 on Wednesday. The company has a market cap of $7.95 billion, a P/E ratio of -16.22 and a beta of 0.65. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The firm’s 50 day moving average price is $133.19 and its 200 day moving average price is $133.40.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. Rhumbline Advisers grew its stake in Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the last quarter. Profund Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 85 shares during the period. Marshall Wace LLP grew its position in shares of Ascendis Pharma A/S by 20.8% during the second quarter. Marshall Wace LLP now owns 30,289 shares of the biotechnology company’s stock worth $4,131,000 after acquiring an additional 5,205 shares during the last quarter. First Light Asset Management LLC acquired a new position in shares of Ascendis Pharma A/S in the 2nd quarter valued at $4,931,000. Finally, Fred Alger Management LLC raised its position in Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.